Requests for Startups · Fall 2026

Build where nobody is standing

by Adam Pangelinan·July 20, 2026·6 requests

Every list of startup ideas is a list of opinions. This one started that way too. I sat down and guessed how contested each of these quests already was, and I was wrong about roughly half of them.

So we measured instead. We searched for the companies actually building each idea and counted them. The result rearranged the entire board. Three quests I was sure were wide open turned out to have five or more funded competitors, and the ones I had buried near the bottom turned out to have almost nobody in them.

That is the whole thesis of this season. The most common way to waste a decade is not picking an unimportant problem. It is picking an important problem that forty other well-funded teams already picked, and finding out eighteen months in. Demand is easy to see. Everyone can see it, which is exactly why the head of the demand curve is the most crowded place on Earth.

The opportunity was never the demand. It is the residual: enormous need, and nobody standing there. So every request below carries a number — how many companies we found already building it. Where that number is zero or one, the field is genuinely yours.

A warning that comes with it. Some of these are empty for good reasons. Gene drives are empty partly because the regulatory and consent apparatus is genuinely hard, not merely unbuilt. Read the blocker before you read the opportunity. An open field is sometimes a frontier and sometimes a graveyard, and telling them apart is the actual work.

Priors the data overturned

24 of 31

And every single miss went the same way: 24 of 24 guessed the field emptier than it was. That is a bias, not noise.

I guessed how contested each quest was. The data disagreed, and always in the same direction.

Each row is one quest. The light dot is what I guessed before looking; the dark dot is what a search for real companies actually found. Sorted by size of the error.

my guesswhat the data founda single ringed dot means the guess was right

hover a row for the counts

every miss points right — busier than guessed

7 guesses held

Sourced via Exa Agent against production, 2026-07-20. Bands: open = 0-1 companies found, contested = 2-4, crowded = 5+.

▸ show the numbers

Quest	Guessed	Found	Building	Verdict
The cost-of-family-formation attack	open	crowded	9	overturned
Days-not-months vaccine manufacturing	open	crowded	7	overturned
Far-UVC as building infrastructure	open	crowded	7	overturned
Third places as a business model	open	crowded	7	overturned
Permitting and entitlement as an API	open	crowded	6	overturned
Aging as an FDA-recognized indication	open	crowded	5	overturned
Behind-the-meter battery storage for datacenter power smoothing	open	crowded	5	overturned
The autonomous lab	contested	crowded	9	overturned
The healthspan diagnostic	contested	crowded	9	overturned
Geothermal everywhere via oilfield tooling	contested	crowded	8	overturned
The factory-built housing company that actually scales	contested	crowded	7	overturned
Credentialing that routes around the diploma	contested	crowded	7	overturned
Point-of-care diagnostics under a dollar	contested	crowded	6	overturned
Making natural hydrogen actually flow	contested	crowded	6	overturned
Hundred-hour grid storage	contested	crowded	5	overturned
Pathogen-agnostic early warning	open	contested	4	overturned
The fission permitting unlock	open	contested	4	overturned
Single-encounter curatives for TB	open	contested	4	overturned
The replication layer	open	contested	4	overturned
Graduation-approach cost collapse	open	contested	4	overturned
A sepsis risk score that needs no new hardware	open	contested	4	overturned
Fast grants as a standing product	open	contested	3	overturned
Building the cure, not just the pill, for river blindness	open	contested	3	overturned
Safe, reversible gene-drive vector control	open	contested	2	overturned
The Bloom 2-sigma tutor	crowded	crowded	5	held
Proximity over feeds	contested	contested	4	held
Anticipatory cash as shared infrastructure	contested	contested	4	held
Broad-spectrum antivenom, manufactured at scale	contested	contested	4	held
Underwriting the interconnection queue	contested	contested	4	held
Order-of-magnitude cheaper IVF	contested	contested	2	held
Methane capture for the open dump, not the landfill	open	open	1	held

Single-encounter curatives for TB

demand 86gap 504 already buildingprize $200B

Tuberculosis kills 1.3M people a year and the cure requires 4–6 months of daily adherence most patients cannot sustain. Build the long-acting or single-dose regimen plus the delivery model.

Why now

Long-acting injectable formulation science matured (proven in HIV PrEP); the same toolkit is unapplied to TB at scale.

Who is already in it

Akagera Medicines · PAN-TB Collaboration / Gates MRI (nonprofit) · Unitaid's long-acting rifapentine program (philanthropic fund) · GHIT Fund (nonprofit fund)

attacks Infectious disease (malaria, TB, HIV)

Safe, reversible gene-drive vector control

demand 86gap 502 already buildingprize $200B

Bednets and spraying have plateaued; the mosquito is the delivery system for malaria. Build the safe, reversible, field-deployable gene-drive company for malaria vectors.

Why now

Gene-drive and self-limiting designs reached field-trial readiness; the gating problems are now governance and reversibility, which are buildable.

Who is already in it

Target Malaria (academic/nonprofit consortium, Gates Foundation + Open Philanthropy funded) · Oxitec (owned by Third Security)

attacks Infectious disease (malaria, TB, HIV)

Fast grants as a standing product

demand 73gap 493 already buildingprize $1T

It takes 6–12 months to fund a science idea. Fast Grants proved it can take 48 hours without quality loss. Build the always-on micro-grant rail for frontier research.

Why now

The Fast Grants experiment produced the playbook; no one operationalized it as durable infrastructure.

Who is already in it

Longevity Impetus Grants (nonprofit) · Renaissance Philanthropy (nonprofit) · Asothia (nonprofit-funded, Coefficient Giving)

attacks Scientific productivity

Permitting and entitlement as an API

demand 79gap 356 already buildingprize $300B

A single-family home waits months on discretionary review that produces no safety value. Build the software that turns zoning + permitting from a black box into a queryable, deterministic API.

Why now

Municipal records are digitizing and LLMs can finally parse zoning code reliably enough to be load-bearing.

Who is already in it

ReadyPermit.AI (OffGrid) · Archistar · Symbium · Zoneomics · PermitFlow · National Zoning Atlas (academic/nonprofit, Cornell)

attacks Low-cost housing & construction

Point-of-care diagnostics under a dollar

demand 86gap 346 already buildingprize $200B

You cannot treat what you cannot diagnose, and PCR needs a lab, cold chain, and a day. Build the paper or CRISPR diagnostic that returns an accurate result anywhere for pennies.

Why now

CRISPR-based detection (SHERLOCK/DETECTR-class) moved from papers to manufacturable formats.

Who is already in it

VPCIR Biosciences · Molbio Diagnostics · Mologic / Global Access Health (nonprofit) · Sherlock Biosciences · FIND (nonprofit foundation) · Qure.ai

attacks Infectious disease (malaria, TB, HIV)

Aging as an FDA-recognized indication

demand 82gap 355 already buildingprize $3T

You cannot run a trial for a disease the regulator does not recognize. Build the company that runs the TAME-class trial and operationalizes aging biomarkers as approvable endpoints.

Why now

Biomarker science (epigenetic and proteomic clocks) matured enough to be candidate endpoints; the regulatory path is the remaining frontier.

Who is already in it

ANI.AI · Vera Genetics · TAME trial / AFAR (academic) · Life Biosciences · Biomarkers of Aging Consortium (academic/nonprofit)

attacks Longevity & aging

If one of these grips you and will not let go, that is the signal. Not that it is clever, not that it is fundable, but that you cannot stop thinking about it. Build it, and tell me what you find. If you are the person already inside one of these problems and I have the numbers wrong, tell me that instead. This index is a conjecture, and the fastest way to improve it is to be refuted by someone doing the work.

— Adam Pangelinan, July 20, 2026

Every request above is drawn from the live power rankings, scored as demand × quest-gap × readiness. Demand comes from the demand map (burden, willingness to pay, capital, research, queues). Competitor counts are sourced, not estimated. Who might fund it is on the capital map.

Weekly whitepaper drop

One problem.One whitepaper. Every week.

Each week we ship a deep-dive whitepaper on a top-ranked humanity-scale problem — built in the spirit of Musk’s Hyperloop Alpha and the transformer paper. Problem + market size + before/after vision + a proposed solution + the investors who would back it. Humanity’s Requests for Startups, sourced and sorted quantitatively. No spam. No marketing.

optimism.fun uses your email address only to send low-volume project updates through Resend. You can unsubscribe with one click at any time; read the privacy policy.

the three routings

1 · weekly whitepaper

one humanity-scale problem per week, deep-dived to whitepaper depth. ships every monday.

2 · founder → problem match

if you’re building, we’ll route you toward the problem and capital stack you fit.

3 · allocator → deal flow

if you’re deploying capital, curated quest-mapped deal flow in the domains you care about.